Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
Cannabis Provisional Patent #62466209, a provisional patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution.
Think about it, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks over its closest competitor. If tests results are similar to Viabecline, for the MMJ space, do you think any other product on the planet will be able to compete with them?
We are talking $$'s when this happens, or a big buyout!
www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
All these companies will want licensing agreements for the Cannabis Provisional Patent #62466209
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
Great post trademax42! I will add to it later tonight.
$VDRM
Check out the latest $VDRM TWITTER feeds!!
Big gap up in the AM!!
$VDRM
.10-12+ coming! BOOOOM
This will spread big time tonight! Check out $VDRM and latest under twitter! This will be on all feeds tonight!!
Plus the conference March 23-25...tomorrow it starts!!
Starosolska, Joanna <Joanna.Starosolska@bcm.edu>
9:39 AM Wednesday, March 15, 2017
to me
Good morning,
Dr. Otiko has been invited to present his poster during the poster session at DFCon. This is a formal session, but it is not an exclusive speaking event.
Poster session will take place on March 24 from 11:40 am to 2:20 pm.
With kind regards,
Joanna Starosolska
Administrative Secretary
Division of Vascular Surgery
Baylor College of Medicine
One Baylor Plaza, MS 390
Houston, TX 77030
Ph: 713-798-7851
Fx: 713-798-2744
DFCon 2017
cid:image004.jpg@01D12770.3F6AF6
GAPPER coming!! BIG buys coming in!!
BOOOM time!!
Gotta love our little $VDRM
On the last 3 runs after a good PR, we gapped up following a surge in volume, much like today.
I feel we will close around .045 and will gap up over .05 in the AM running to .075-.085. A pull back at that point would be expected but...
This PR is different in many ways..
1- Conference starts tomorrow, check my post on attendees. MANY new eyes will be looking at ViaDerma, and with DEEP pockets!
2- Sales are currently expected to be around 500,000 units at $125 in 2017. That's $62,500,000. There could be many possible sales agreements made during/post conference.
3- MMJ play with a Canadian company could be a diamond in the rough for our little company. Realize we are only trading at a Market Cap of about 10mill right now.
I think the excitement builds tonight and runs into tomorrow..
Long $VDRM
Is anyone going to this event?!?
BOOOM time coming!!
$VDRM
Look at the companies in attendance! Let alone all the 100's of DOCs attending from all over the world!!
MASSIVE move coming !
Conference will be BIG for ViaDerma!! March 23-25, this week..
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
Sponsors
EDUCATIONAL GRANTS
This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity
PLATINUM
Abbott Laboratories
BRONZE
Boston Scientific
Cardiovascular Systems, Inc.
Fashek Family Foundation
EXHIBITS, SYMPOSIA AND WORKSHOP SPONSORS
Support for this conference has been provided in part by the following exhibitor, symposium and workshop sponsors:
PLATINUM
Acelity
Abbott Vascular
BSN medical, Inc.
Integra LifeSciences
SILVER
Boston Scientific
Cook Medical
EO2 Concepts
W.L. Gore
MiMedx
NOVADAQ
Osiris Therapeutics
Tissue Regenix
Woundcare-Circle
BRONZE
Acell
Alliqua BioMedical
Anvil Orthotics
Arobella Medical LLC
Derma Sciences
Footbeat
Hanger Clinic
Herreen
Medela LLC
MedShape, Inc.
Misonix
MTF Wound Care
Organogenesis
Philips Volcano
Restorative Medical
RestorixHealth
Spectranetics
Siren Care
Stryker
FRIENDS OF DFCON
8th International Symposium on the Diabetic Foot
First Nations Limb Preservation Foundation
Wound Healing Society/Wound Healing Foundation
Inquires: dfcon@bcm.edu
We should be trading over .25 right now!!
$VDRM
Lol! You can check my posts. I've been here since .006, and hold many many shares here! My biggest otc holding, and most exciting!! I've done extensive DD on this company and I know what's at play.
Just know this is just the start!! There will be days ahead soon when we will be having multiple $100mill trading days!
Our Market Cap is insanely LOW!!
Longs will be very wealthy with this ticker!
$VDRM
ViaDerma's time has come!! .10-12+ post conference, maybe this week!
~ 100's of DOCs from around the world will see what our good Doc has been researching, developing, for over 7 years!! And now has provisional pending patent application #'s to back it up! Look at the list of COMPANIES at DFCon!!! Huge!! Massive $$ will pour in!!
~ sales of 500,000 units at $125/ rolling out in 2017! Check PRs posted on my sticky above.
~ LOI signed with a Canadian company to roll out licensing/distribution... if results come in positive, we're taking multi $$'s!! Canada is one of the world leaders in the MMJ space! Google Canadian MJ companies!! Huge potential there!
BOOOOM time people! Ride the waves, I hate to predict but our 'little' company may not be so 'little' soon!!
$VDRM
READ my sticky's above!!
.10-12+ coming!! Hang on
Gap up in the AM
$VDRM
We're all over twitter! When charts get viewed tonight, we will GAP UP in the AM!
Same thing happened last run! However, with the conference starting tomorrow and running through Friday, big $$ will pour in late this week and Monday/Tuesday next week.
.10-12+ this week, who knows next week?? .15+??
BOOOOM
$VDRM
BOOOOOM!! When 50mill+ volume shows up tomorrow we will break .10-12+!!
$VDRM
.10-12+ coming! Wait until all the DOCs $$ start pouring in!
Then all the MMJ $$
BOOOOM!!
$VDRM
People have no idea how big this news is!!
Last month we ran from .018 to .069 3 days after news! This news is much BIGGER!
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
Join AvaTrade and we’ll match your first deposit of $300, giving you $600 to trade.
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit:
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
Join AvaTrade and we’ll match your first deposit of $300, giving you $600 to trade.
Just wait until post conference!! This ticker is going to BLOW UP!!
.10-12+
Love ViaDerma!!
$VDRM
BOOOOM!! Saaaweet move today!!
.10-12+ post conference! I've been calling that for 8 weeks now!
Wait till all the DOCS from around the world see ViaDerma this week!!
$VDRM
Sunnyland!! Great to have you and your gang here!!
.10-12+ coming!!
$VDRM
Loving the action today!! Newbies READ my sticky's above!!
.10-12+ post conference!!
BOOOOOM
$VDRM
BREAKOUT!! Boom time!!!
$VDRM
www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
Conference will be BIG for ViaDerma!! March 23-25, this week..
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
Sponsors
EDUCATIONAL GRANTS
This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity
PLATINUM
Abbott Laboratories
BRONZE
Boston Scientific
Cardiovascular Systems, Inc.
Fashek Family Foundation
EXHIBITS, SYMPOSIA AND WORKSHOP SPONSORS
Support for this conference has been provided in part by the following exhibitor, symposium and workshop sponsors:
PLATINUM
Acelity
Abbott Vascular
BSN medical, Inc.
Integra LifeSciences
SILVER
Boston Scientific
Cook Medical
EO2 Concepts
W.L. Gore
MiMedx
NOVADAQ
Osiris Therapeutics
Tissue Regenix
Woundcare-Circle
BRONZE
Acell
Alliqua BioMedical
Anvil Orthotics
Arobella Medical LLC
Derma Sciences
Footbeat
Hanger Clinic
Herreen
Medela LLC
MedShape, Inc.
Misonix
MTF Wound Care
Organogenesis
Philips Volcano
Restorative Medical
RestorixHealth
Spectranetics
Siren Care
Stryker
FRIENDS OF DFCON
8th International Symposium on the Diabetic Foot
First Nations Limb Preservation Foundation
Wound Healing Society/Wound Healing Foundation
Inquires: dfcon@bcm.edu
Cannabis Provisional Patent #62466209, a provisional patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution.
Think about it, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks over its closest competitor. If tests results are similar to Viabecline, for the MMJ space, do you think any other product on the planet will be able to compete with them?
We are talking $$'s when this happens, or a big buyout!
http://www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
All these companies will want licensing agreements for the Cannabis Provisional Patent #62466209
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
LOL!!! bahahaha you don't get invited to http://dfcon.com/ unless you have something pretty special!!
Read my sticky's above;)
KABOOOM
$VDRM
LOL! Prove it
BOOOOM
.10-12+ coming
$VDRM
Proof is in the pudding!! We have provisional patent #s!!
Hype hasn't even started yet!!
Just wait until 100's of DOCs from all over the world see ViaDerma's technology and potential this week! .10-12+ coming!!
BOOOOOM.
$VDRM
LOL!! Prove it!
BOOM time for this ticker!!!
$VDRM
Proof is in the number! ViaDerma is going to DOMINATE the market.
$100,000,000+ market cap will come, this is why the CEO hired an Investors Relations specialist.
See my 2 sticky's above!
BOOOOOOM!!
$VDRM
$VDRM ~ Huge News!!
http://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Receives-Provisional-Patent-Numbers-for-Its-FDA-Registered-Viabecline-and-Cannabis-Technologies--and-Seeks-to-Distribute-its-Products-with-a-Management--Marketing-and-Distribution-Company-in-Canada-to-Approved-International-Cannabis-Countries?id=153729&b=y
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
That's from 2012! Provide us with a provisional patent number for Diabecline?? The patent was abandoned by Pharmacline. They are no longer selling the product either. Look at the inactive ingredients, they are different as well. BOOOOOOM
Dr. Otiko has filed a provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses for Viabecline, which has different ingredients.
https://www.drugs.com/otc/676986/viabecline.html
https://www.drugs.com/otc/105987/diabecline.html
BOOOOOOOOOM time!!!!
.10-12+ coming
Long $VDRM
READ all 3 of my posts below if you are considering an investment here.
Multi week runner has started!
https://twitter.com/search?f=tweets&vertical=default&q=vdrm&src=typd
Long $VDRM
Conference will be BIG for ViaDerma!! March 23-25, this week..
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
Sponsors
EDUCATIONAL GRANTS
This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity
PLATINUM
Abbott Laboratories
BRONZE
Boston Scientific
Cardiovascular Systems, Inc.
Fashek Family Foundation
EXHIBITS, SYMPOSIA AND WORKSHOP SPONSORS
Support for this conference has been provided in part by the following exhibitor, symposium and workshop sponsors:
PLATINUM
Acelity
Abbott Vascular
BSN medical, Inc.
Integra LifeSciences
SILVER
Boston Scientific
Cook Medical
EO2 Concepts
W.L. Gore
MiMedx
NOVADAQ
Osiris Therapeutics
Tissue Regenix
Woundcare-Circle
BRONZE
Acell
Alliqua BioMedical
Anvil Orthotics
Arobella Medical LLC
Derma Sciences
Footbeat
Hanger Clinic
Herreen
Medela LLC
MedShape, Inc.
Misonix
MTF Wound Care
Organogenesis
Philips Volcano
Restorative Medical
RestorixHealth
Spectranetics
Siren Care
Stryker
FRIENDS OF DFCON
8th International Symposium on the Diabetic Foot
First Nations Limb Preservation Foundation
Wound Healing Society/Wound Healing Foundation
Inquires: dfcon@bcm.edu
www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
Cannabis Provisional Patent #62466209, a provisional patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution.
Think about it, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks over its closest competitor. If tests results are similar to Viabecline, for the MMJ space, do you think any other product on the planet will be able to compete with them?
We are talking $$'s when this happens, or a big buyout!
http://www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
All these companies will want licensing agreements for the Cannabis Provisional Patent #62466209
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
Check the volume below. Last time we ran from .018 to .069. The volume was similar to a 4 day period Feb 14-17, as its been the past 4 days. I think the volume will come Tuesday or Wednesday, if it does, I believe we will run to .08-.12 this run. We're all over twitter, and popping up in different news feeds. Charts experts are calling for a run this week.
https://twitter.com/search?f=tweets&vertical=default&q=vdrm&src=typd
Given the GREAT news release today and with the conference happening March 23-25, I think we have a good chance of breaking .10 post conference, if not before.
https://twitter.com/BigCheds
Mar 20, 2017 0.03 0.03 0.02 0.03 12,268,944
Mar 17, 2017 0.03 0.03 0.02 0.02 10,745,424
Mar 16, 2017 0.03 0.03 0.02 0.03 10,456,039
Mar 15, 2017 0.03 0.03 0.02 0.02 5,129,318
Mar 14, 2017 0.03 0.03 0.02 0.03 7,814,388
Mar 13, 2017 0.03 0.03 0.02 0.03 15,767,545
Mar 10, 2017 0.03 0.03 0.03 0.03 6,770,329
Mar 9, 2017 0.04 0.04 0.03 0.03 12,253,311
Mar 8, 2017 0.04 0.04 0.03 0.03 8,601,700
Mar 7, 2017 0.03 0.04 0.03 0.04 11,276,437
Mar 6, 2017 0.04 0.04 0.03 0.03 22,147,198
Mar 3, 2017 0.04 0.04 0.04 0.04 7,969,201
Mar 2, 2017 0.05 0.05 0.04 0.04 10,554,184
Mar 1, 2017 0.04 0.05 0.04 0.05 15,202,968
Feb 28, 2017 0.04 0.04 0.04 0.04 15,547,673
Feb 27, 2017 0.05 0.05 0.04 0.04 23,258,917
Feb 24, 2017 0.06 0.06 0.05 0.05 15,100,045
Feb 23, 2017 0.07 0.07 0.05 0.06 22,457,091
Feb 22, 2017 0.04 0.06 0.04 0.06 61,580,510
Feb 21, 2017 0.02 0.04 0.02 0.04 55,088,906
Feb 17, 2017 0.02 0.02 0.02 0.02 10,654,273
Feb 16, 2017 0.02 0.02 0.02 0.02 16,527,367
Feb 15, 2017 0.02 0.02 0.02 0.02 14,484,352
Feb 14, 2017 0.02 0.02 0.02 0.02 7,316,923
Feb 13, 2017 0.02 0.03 0.02 0.02 15,618,023
Feb 10, 2017 0.03 0.03 0.02 0.02 22,450,192
Feb 9, 2017 0.03 0.03 0.03 0.03 30,179,487
Feb 8, 2017 0.02 0.03 0.02 0.03 19,825,463
Feb 7, 2017 0.03 0.04 0.02 0.02 49,340,847
Feb 6, 2017 0.01 0.03 0.01 0.03 37,724,514
I'm liking what I see here! Been in and out of this stock for the past week.
Going to hold a longer term position now. Let's see what happens!
My other 2 pharma biotech/MMJ stocks and USRM, are going to play out very well for me this year!!
GLTA who hold here!
Still holding 80,000 shares here!
My 2 pharma biotech/ MMJ stocks are going to play out very well for me this year!
Would like to see OWCP make another run soon..
I think we will hit that by the end of March.
Long $VDRM